Auranofin
General information
Auranofin, a gold-containing triethyl phosphine, is an FDA- approved drug for the treatment of rheumatoid arthritis since 1985. It has been investigated for potential therapeutic applications in a number of other diseases including cancer, neurodegenerative disorders, HIV/AIDS, parasitic infections, and bacterial infections. Recently, auranofin was approved by the FDA for phase II clinical trials for cancer therapy.
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
The FDA- approved gold drug Auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells
|
Huh7 cells | Apr/15/2020 | ||
|
Molecules inhibit the enzyme activity of 3-chymotrypsin-like cysteine protease of SARS-CoV-2 virus: the experimental and theory studies
Preprint |
in vitro | May/29/2020 |
